-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SYNCAR-001 in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SYNCAR-001 in Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SYNCAR-001 in Non-Hodgkin Lymphoma Drug Details: SYNCAR-001 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – UCLM-802 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - UCLM-802 in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. UCLM-802 in Gastric Cancer Drug Details: UCLM-802 is under development for the...
-
Product Insights
NewB-Cell Chronic Lymphocytic Leukemia – Drugs In Development, 2024
Empower your strategies with our B-Cell Chronic Lymphocytic Leukemia – Drugs In Development, 2024 report and make more profitable business decisions. B-cell chronic lymphocytic leukemia is a type of slow-growing leukemia that affects developing B-lymphocytes (also known as B-cells). Symptoms include swollen lymph nodes (glands) in the neck, under the arms, or in the groin; pain or discomfort under the ribs on the left side due to an enlarged spleen; frequent or repeated infections and slow healing, due to a lack...
-
Product Insights
NewPrimary CNS Lymphoma – Drugs In Development, 2024
Empower your strategies with our Primary CNS Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Primary CNS lymphoma (PCNSL) is a rare extranodal lymphoma that affects the brain, spinal cord, leptomeninges, or vitreoretinal space, without evidence of systemic involvement. It is a subtype on, and one of the most aggressive forms of, diffuse large B-cell lymphoma. PCNSL is more common in immunosuppressed patients, such as those with HIV/AIDS or transplant recipients, and is often associated with...
-
Product Insights
NewWaldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) – Drugs In Development, 2024
Empower your strategies with our Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) – Drugs In Development, 2024 report and make more profitable business decisions. Waldenstrom macroglobulinemia, one of the malignant monoclonal gammopathies, is a chronic, indolent, lymphoproliferative disorder. It is characterized by the presence of a high level of a macroglobulin (immunoglobulin M [IgM]), elevated serum viscosity, and the presence of a lymphoplasmacytic infiltrate in the bone marrow. Waldenström macroglobulinemia is considered to be a lymphoplasmacytic lymphoma, as defined by the Revised European American...
-
Product Insights
NewB-Cell Leukemia – Drugs In Development, 2024
Empower your strategies with our B-Cell Leukemia – Drugs In Development, 2024 report and make more profitable business decisions. B-cell leukemia is a type of blood cancer that originates in the bone marrow, affecting B lymphocytes (B cells), a crucial component of the immune system. This leukemia results in the uncontrolled growth and accumulation of abnormal B cells, which hinder the normal production of healthy blood cells. Diagnosis involves blood tests, bone marrow biopsies, and imaging scans to identify and classify...
-
Product Insights
NewPeripheral T-Cell Lymphomas (PTCL) – Drugs In Development, 2024
Empower your strategies with our Peripheral T-Cell Lymphomas (PTCL) – Drugs In Development, 2024 report and make more profitable business decisions. Peripheral T-cell lymphomas (PTCL) constitute a diverse group of rare and aggressive non-Hodgkin lymphomas originating from mature T cells. These malignancies involve lymphoid tissues and may affect organs throughout the body. PTCLs are heterogeneous, comprising various subtypes with distinct clinical behaviors and outcomes. Symptoms may include enlarged lymph nodes, fever, weight loss, and night sweats. Diagnosis involves biopsies, imaging studies,...
-
Product Insights
NewSecondary CNS Lymphoma – Drugs In Development, 2024
Empower your strategies with our Secondary CNS Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Lymphoma in CNS (parts of the brain) is known as secondary CNS lymphoma (SCNSL). It is a form of CNS lymphoma where the risk of developing secondary lymphoma is 5-15%. It involves brain, eyes, spinal cord, meninges, as these are BBB (blood brain barriers) it creates a therapeutic challenge in managing this condition while relapse of the condition is also seen....
-
Product Insights
NewMarginal Zone B-cell Lymphoma – Drugs In Development, 2024
Empower your strategies with our Marginal Zone B-cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Marginal zone B-cell lymphoma is a slow-growing, non-Hodgkin lymphoma that originates from B cells at the margins of lymphoid tissues. It's divided into three subtypes: extranodal, nodal, and splenic, each with distinct features. Extranodal marginal zone lymphoma primarily affects organs outside the lymph nodes, such as the stomach (gastric MALT lymphoma) or the eye (ocular MALT lymphoma). Symptoms may include...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Human Amniotic Epithelial Stem Cells in Premature Ovarian Failure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Human Amniotic Epithelial Stem Cells in Premature Ovarian Failure report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Human Amniotic Epithelial Stem Cells in...